Savient Pharmaceuticals
As of the edition of 20 October 2026, Savient Pharmaceuticals runs 3 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tamoxifen | none listed | 0 |
| Pegloticase | Ended 2022 (computed from the first US licence) | 0 |
| Oxandrolone | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Bones, joints and muscles: 4 trials led
- Inherited and neonatal: 4 trials led
- Nutrition and metabolism: 4 trials led